Executive Briefing Series (formerly The Food & Drug Letter)
Sept. 7, 2012
During three workshop training sessions, the International Conference on Harmonisation (ICH) Quality Implementation Working Group (Q-IWG) heard dozens of questions about its Q8, Q9 and Q10 guidelines. As a result, the working group prepared a recently released “Points to Consider” document covering topics relevant to the implementation of the three quality guidelines. These are intended to supplement the existing guidance Q8 (R2), Q9, Q10 and Questions & Answers and workshop training materials already produced by this group. These points are intended to provide clarity to both industry and regulators and to facilitate the preparation, assessment, and inspection related to applications filed for marketing authorizations. This issue of The Food & Drug Letter excerpts those points to consider. ICH emphasizes that applicants’ development approach should be adapted based on the complexity and specificity of product and process. Using the Quality by Design (QbD) approach does not change regional regulatory requirements but can provide opportunities for more flexible approaches to meet them. In all cases, good manufacturing practice (GMP) compliance is expected.
This article is viewable by subscribers only. To view this article, please select an option below.
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!